作者
Bryan H King, Eric Hollander, Linmarie Sikich, James T McCracken, Lawrence Scahill, Joel D Bregman, Craig L Donnelly, Evdokia Anagnostou, Kimberly Dukes, Lisa Sullivan, Deborah Hirtz, Ann Wagner, Louise Ritz
发表日期
2009/6/1
期刊
Archives of general psychiatry
卷号
66
期号
6
页码范围
583-590
出版商
American Medical Association
简介
Context
Selective serotonin reuptake inhibitors are widely prescribed for children with autism spectrum disorders.
Objectives
To determine the efficacy and safety of citalopram hydrobromide therapy for repetitive behavior in children with autism spectrum disorders.
Design
National Institutes of Health–sponsored randomized controlled trial.
Setting
Six academic centers, including Mount Sinai School of Medicine, North Shore–Long Island Jewish Health System, University of North Carolina at Chapel Hill, University of California at Los Angeles, Yale University, and Dartmouth Medical School.
Participants
One hundred forty-nine volunteers 5 to 17 years old (mean [SD] age, 9.4 [3.1] years) were randomized to receive citalopram (n = 73) or placebo (n = 76). Participants had autistic spectrum disorders, Asperger disorder, or pervasive developmental disorder, not otherwise specified; had illness severity ratings of at least …
引用总数
学术搜索中的文章
BH King, E Hollander, L Sikich, JT McCracken… - Archives of general psychiatry, 2009
